Merck: Positive Phase 1 Data for Islatravir Subdermal Implant for HIV-1 Prevention
By Colin Kellaher
Merck & Co. on Monday reported positive results from a Phase
1 study evaluating the safety, tolerability and pharmacokinetics of
its investigational islatravir subdermal implant for the prevention
of HIV-1 infection.
The Kenilworth, N.J., drugmaker said the data support the
potential for a once-yearly dosing regimen for islatravir using a
subdermal implant for pre-exposure prophylaxis, or "PrEP," of HIV-1
Merck said the implant achieved active drug concentrations above
the pre-specified threshold at 12 weeks across the three doses of
islatravir studied and is projected to provide drug concentrations
likely above threshold for one year at the highest dose.
Based on the findings, Merck said it plans to launch a Phase 2
trial to further explore the potential of a subdermal implant
containing islatravir as a long-acting option for PrEP for up to 12
The company is studying islatravir across a variety of doses,
formulations and frequencies for both the treatment of HIV-1
infection in combination with other antiretroviral agents and for
the prevention of HIV-1 infection as a single agent.
Shares of Merck rose nearly 3% in midday trading Monday.
Write to Colin Kellaher at firstname.lastname@example.org
(END) Dow Jones Newswires
March 08, 2021 12:17 ET (17:17 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.